Publications by Mads Haugland Haugen

35 publications found

Publications 2024

1. Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L (2024)
   The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
   Br J Cancer, 131 (10), 1656-1667
   DOI 10.1038/s41416-024-02875-5, PubMed 39390250
2. Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
   An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
   Mol Oncol, 18 (8), 2042-2059
   DOI 10.1002/1878-0261.13656, PubMed 38671580

Publications 2023

1. Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O (2023)
   Liver X receptors induce antiproliferative effects in basal-like breast cancer
   Mol Oncol, 17 (10), 2041-2055
   DOI 10.1002/1878-0261.13476, PubMed 37341140
2. Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
   High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
   PLoS One, 18 (1), e0280507
   DOI 10.1371/journal.pone.0280507, PubMed 36706086
3. Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
   A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
   Cancer Res Commun, 3 (2), 235-244
   DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142

Publications 2022

1. Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK (2022)
   miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
   Breast Cancer (Dove Med Press), 14, 25-39
   DOI 10.2147/BCTT.S338404, PubMed 35256859
2. Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
   AXL inhibition improves BRAF-targeted treatment in melanoma
   Sci Rep, 12 (1), 5076
   DOI 10.1038/s41598-022-09078-z, PubMed 35332208

Publications 2021

1. Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
   Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
   JCO Precis Oncol, 5
   DOI 10.1200/PO.20.00086, PubMed 34036235
2. Normann LS, Aure MR, Leivonen SK, Haugen MH, Hongisto V, Kristensen VN, Mælandsmo GM, Sahlberg KK (2021)
   MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
   Sci Rep, 11 (1), 10893
   DOI 10.1038/s41598-021-90385-2, PubMed 34035375
3. Tamhane T, Njenga RW, Burden RE, Bueth H, Maelandsmo GM, Haugen MH, Scott CJ, Brix K (2021)
   Trafficking of Full-Length and N-Terminally Truncated Cathepsin B in Human Colorectal Carcinoma Cells
   Appl. Sci.-Basel, 11 (24), 11936
   DOI 10.3390/app112411936

Publications 2020

1. Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
   Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
   Front Oncol, 10, 590755
   DOI 10.3389/fonc.2020.590755, PubMed 33324562
2. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Krauss S, Olberg DE, Waaler J, Klaveness J (2020)
   Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
   RSC Adv, 10 (9), 4927
   DOI 10.1039/d0ra90007a, PubMed 35503286

Publications 2019

1. Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
   Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
   Mol Cancer Ther, 19 (3), 895-905
   DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
2. Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
   Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
   Breast Cancer Res, 21 (1), 61
   DOI 10.1186/s13058-019-1141-0, PubMed 31088535
3. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
   Breast cancer quantitative proteome and proteogenomic landscape
   Nat Commun, 10 (1), 1600
   DOI 10.1038/s41467-019-09018-y, PubMed 30962452
4. Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J (2019)
   Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
   RSC Adv, 9 (63), 37092-37100
   DOI 10.1039/c9ra08954c, PubMed 35539091
5. Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
   Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
   Arch Pharm (Weinheim), 352 (9), e1900101
   DOI 10.1002/ardp.201900101, PubMed 31414521
6. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
   miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
   Mol Oncol, 13 (10), 2278-2296
   DOI 10.1002/1878-0261.12561, PubMed 31402562

Publications 2018

1. Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
   Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
   Mol Oncol, 12 (9), 1540-1558
   DOI 10.1002/1878-0261.12319, PubMed 29741811
2. Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
   Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
   Cancer Lett, 439, 1-13
   DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

1. Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, Rut W, Drag M, Poreba M, Johansen HT, Solberg R (2017)
   Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions
   Biochimie, 139, 27-37
   DOI 10.1016/j.biochi.2017.05.009, PubMed 28528272

Publications 2016

1. Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
   Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
   Nature, 537 (7621), 548-552
   DOI 10.1038/nature19360, PubMed 27626377
2. Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
   The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
   PLoS One, 11 (12), e0167754
   DOI 10.1371/journal.pone.0167754, PubMed 28002446
3. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
   Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
   Oncotarget, 7 (15), 19997-20015
   DOI 10.18632/oncotarget.7671, PubMed 26918352

Publications 2015

1. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
   Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
   Clin Exp Metastasis, 32 (8), 755-67
   DOI 10.1007/s10585-015-9742-1, PubMed 26349943
2. Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K (2015)
   Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells
   Biochimie, 122, 208-18
   DOI 10.1016/j.biochi.2015.09.003, PubMed 26343556
3. Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K (2015)
   Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
   Data Brief, 5, 468-75
   DOI 10.1016/j.dib.2015.09.022, PubMed 26594658

Publications 2014

1. Brix K, McInnes J, Al-Hashimi A, Rehders M, Tamhane T, Haugen MH (2014)
   Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges
   Protoplasma, 252 (3), 755-74
   DOI 10.1007/s00709-014-0730-0, PubMed 25398648
2. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
   High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
   Eur J Cancer, 51 (1), 9-17
   DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Publications 2013

1. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
   Nuclear legumain activity in colorectal cancer
   PLoS One, 8 (1), e52980
   DOI 10.1371/journal.pone.0052980, PubMed 23326369

Publications 2012

1. Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R (2012)
   Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M
   Biochimie, 94 (12), 2590-9
   DOI 10.1016/j.biochi.2012.07.026, PubMed 22902879

Publications 2010

1. Berge G, Andersen K, Haugen MH, Maelandsmo GM (2010)
   Comment on the Importance of S100A4 in regulation of MMP-13
   J Biol Chem, 285 (53), le23; author reply le24
   DOI 10.1074/jbc.L110.125898, PubMed 21186294
2. Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R (2010)
   Cystatin E/M suppresses legumain activity and invasion of human melanoma
   BMC Cancer, 10, 17
   DOI 10.1186/1471-2407-10-17, PubMed 20074384
3. Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
   TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
   Tumour Biol, 32 (1), 1-12
   DOI 10.1007/s13277-010-0073-1, PubMed 20652782

Publications 2008

1. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
   The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
   BMC Cancer, 8, 172
   DOI 10.1186/1471-2407-8-172, PubMed 18554396